Advanced

hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review.

Nordh, Stina; Ansari, Daniel LU and Andersson, Roland LU (2014) In World Journal of Gastroenterology 20(26). p.8482-8490
Abstract
High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. Relevant articles were obtained from PubMed, Embase and Cochrane databases. Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. Outcome measures were overall survival, disease-free survival (DFS), toxicity and response rate. The database searches identified 10 studies that met the eligibility criteria, and a total of 855 patients were... (More)
High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. Relevant articles were obtained from PubMed, Embase and Cochrane databases. Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. Outcome measures were overall survival, disease-free survival (DFS), toxicity and response rate. The database searches identified 10 studies that met the eligibility criteria, and a total of 855 patients were included. Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression. In the 7 studies that reported DFS as an outcome measure, 6 had statistically longer DFS in the high hENT1 groups. Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions. This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine. Some limitations of the review have to be taken into consideration, the majority of the included studies had a retrospective design, and there was no standardized scoring protocol for hENT1-expression. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
World Journal of Gastroenterology
volume
20
issue
26
pages
8482 - 8490
publisher
WJG Press
external identifiers
  • pmid:25024604
  • wos:000339389500013
  • scopus:84904395417
ISSN
1007-9327
DOI
10.3748/wjg.v20.i26.8482
language
English
LU publication?
yes
id
c8726bd9-a1bb-4ebc-a4e4-8753a4111881 (old id 4582264)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25024604?dopt=Abstract
date added to LUP
2014-08-08 00:00:26
date last changed
2017-11-19 03:21:53
@article{c8726bd9-a1bb-4ebc-a4e4-8753a4111881,
  abstract     = {High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. Relevant articles were obtained from PubMed, Embase and Cochrane databases. Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. Outcome measures were overall survival, disease-free survival (DFS), toxicity and response rate. The database searches identified 10 studies that met the eligibility criteria, and a total of 855 patients were included. Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression. In the 7 studies that reported DFS as an outcome measure, 6 had statistically longer DFS in the high hENT1 groups. Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions. This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine. Some limitations of the review have to be taken into consideration, the majority of the included studies had a retrospective design, and there was no standardized scoring protocol for hENT1-expression.},
  author       = {Nordh, Stina and Ansari, Daniel and Andersson, Roland},
  issn         = {1007-9327},
  language     = {eng},
  number       = {26},
  pages        = {8482--8490},
  publisher    = {WJG Press},
  series       = {World Journal of Gastroenterology},
  title        = {hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review.},
  url          = {http://dx.doi.org/10.3748/wjg.v20.i26.8482},
  volume       = {20},
  year         = {2014},
}